This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Richards, A. M. Articles by Frampton, C. Search for Related Content PubMed PubMed Citation Articles by Richards, A. M. Articles by Frampton, C.

Hypertension, Vol 22, 119-126, Copyright © 1993 by American Heart Association

ARTICLES

Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension

AM Richards, IG Crozier, T Kosoglou, M Rallings, EA Espiner, MG Nicholls, TG Yandle, H Ikram and C Frampton
Department of Cardiology, Princess Margaret Hospital, Christchurch, New Zealand.

The detailed integrated renal, hormonal, and hemodynamic effects of acute (first dose) and established (4 days) inhibition of endopeptidase 24.11 by SCH 42495 (200 mg, every 12 hours) were documented in eight patients with essential hypertension in a double-blind, balanced random- order, crossover study. SCH 42495 suppressed plasma endopeptidase activity (> 90%, P < .001) for the duration of the dosing period. Initially, plasma atrial natriuretic factor levels increased markedly (+123%, P < .01) and remained elevated, although to a lesser extent (+34%, P < .01), with established enzyme inhibition. Cyclic guanosine monophosphate in both plasma and urine remained elevated throughout the treatment period. Significant augmentation of sodium excretion in excess of placebo values (96 +/- 27 mmol sodium, P < .001) was established in the initial 24 hours of dosing but later became attenuated, with a mild antinatriuresis (P < .01) in the latter 3 days of treatment. Blood pressure, heart rate, the renin-angiotensin- aldosterone system, and plasma norepinephrine levels were all initially (first dose) unchanged. With established enzyme inhibition (day 4), however, blood pressure was significantly lower (mean 24-hour values, 9.3 +/- 3/-3.8 +/- 1 mm Hg, P < .05 for both systolic and diastolic pressures) than matched placebo values, whereas heart rate was higher (2.7 +/- 1 beats per minute, P < .01). Mean 24-hour values of plasma renin activity (+33%, P < .05), aldosterone (+36%, P < .05), and norepinephrine (+40%, P < .001) were all clearly increased above placebo values with established enzyme inhibition.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				S. I. McFarlane, N. Winer, and J. R. Sowers Role of the Natriuretic Peptide System in Cardiorenal Protection Arch Intern Med, December 8, 2003; 163(22): 2696 - 2704. [Abstract] [Full Text] [PDF]

				A. C. Rosenkranz, S. G. Hood, R. L. Woods, G. J. Dusting, and R. H. Ritchie B-Type Natriuretic Peptide Prevents Acute Hypertrophic Responses in the Diabetic Rat Heart: Importance of Cyclic GMP Diabetes, September 1, 2003; 52(9): 2389 - 2395. [Abstract] [Full Text] [PDF]

				V. M. Campese, K. C. Lasseter, C. M. Ferrario, W. B. Smith, M. C. Ruddy, C. E. Grim, R. D. Smith, R. Vargas, M. F. Habashy, O. Vesterqvist, et al. Omapatrilat Versus Lisinopril: Efficacy and Neurohormonal Profile in Salt-Sensitive Hypertensive Patients Hypertension, December 1, 2001; 38(6): 1342 - 1348. [Abstract] [Full Text] [PDF]

				L. M. Burrell, N. K. Farina, L. C. Balding, and C. I. Johnston Beneficial Renal and Cardiac Effects of Vasopeptidase Inhibition With S21402 in Heart Failure Hypertension, December 1, 2000; 36(6): 1105 - 1111. [Abstract] [Full Text] [PDF]

				S. Laurent, P. Boutouyrie, M. Azizi, C. Marie, C. Gros, J.-C. Schwartz, J.-M. Lecomte, and J. Bralet Antihypertensive Effects of Fasidotril, a Dual Inhibitor of Neprilysin and Angiotensin-Converting Enzyme, in Rats and Humans Hypertension, May 1, 2000; 35(5): 1148 - 1153. [Abstract] [Full Text] [PDF]

				C. J. Ferro, J. C. Spratt, W. G. Haynes, and D. J. Webb Inhibition of Neutral Endopeptidase Causes Vasoconstriction of Human Resistance Vessels In Vivo Circulation, June 16, 1998; 97(23): 2323 - 2330. [Abstract] [Full Text] [PDF]

				R. E. Chatelain, R. D. Ghai, A. J. Trapani, L. M. Odorico, B. N. Dardik, S. De Lombaert, R. W. Lappe, and C. A. Fink Antihypertensive and Natriuretic Effects of CGS 30440, a Dual Inhibitor of Angiotensin-Converting Enzyme and Neutral Endopeptidase 24.11 J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 974 - 982. [Abstract] [Full Text]